Skip to main content
Michael Friedman, MD, Pathology, Tampa, FL

MichaelI.FriedmanMD

Pathology Tampa, FL

Cytopathology, Anatomic Pathology, Clinical Pathology

Physician

Are you Dr. Friedman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 13 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    3001 W Dr Martin Luther King Jr Blvd
    Tampa, FL 33607
    Phone+1 813-870-4206
    Fax+1 813-870-4853

Summary

  • Dr. Michael Friedman, MD is a board certified pathologist in Tampa, Florida. He is currently licensed to practice medicine in Florida, Georgia, and Ohio. He is affiliated with St. Joseph's Hospital.

Education & Training

  • Emory University School of Medicine
    Emory University School of MedicineFellowship, Cytopathology, 1992 - 1994
  • The MetroHealth System/Case Western Reserve University
    The MetroHealth System/Case Western Reserve UniversityResidency, Pathology-Anatomic and Clinical, 1988 - 1992
  • Mount Sinai Medical Center of Cleveland
    Mount Sinai Medical Center of ClevelandInternship, Transitional Year, 1987 - 1988
  • Stellenbosch University Faculty of Medicine
    Stellenbosch University Faculty of MedicineClass of 1985

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 1994 - 2026
  • GA State Medical License
    GA State Medical License 1991 - 1995
  • OH State Medical License
    OH State Medical License 1989 - 1992
  • TN State Medical License
    TN State Medical License 1988 - 1991
  • American Board of Pathology Anatomic Pathology & Clinical Pathology
  • American Board of Pathology Cytopathology

Press Mentions

  • First Chimeric Antigen Receptor (CAR) T Cell Therapy Targeting B Cell-Activating Factor Receptor (BAFF-R) Eradicates Blood Cancers That Relapsed After CD19 CAR T Therapies
    First Chimeric Antigen Receptor (CAR) T Cell Therapy Targeting B Cell-Activating Factor Receptor (BAFF-R) Eradicates Blood Cancers That Relapsed After CD19 CAR T TherapiesSeptember 25th, 2019
  • First CAR T-cell Therapy Targeting B Cell-Activating Factor Receptor Eradicates Blood Cancers
    First CAR T-cell Therapy Targeting B Cell-Activating Factor Receptor Eradicates Blood CancersSeptember 25th, 2019
  • City of Hope Clinical and Laboratory Investigators Present New Research at the 60
    City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
  • Join now to see all